Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.78 |
| ▸ | LCK | P06239 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | HPGD | P15428 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | CA12 | O43570 | 5/20 | 0.62 |
| ▸ | CA1 | P00915 | 5/20 | 0.62 |
| ▸ | CA2 | P00918 | 5/20 | 0.62 |
| ▸ | CA9 | Q16790 | 4/20 | 0.62 |
| ▸ | CA4 | P22748 | 2/20 | 0.61 |
| ▸ | CA5A | P35218 | 2/20 | 0.61 |
| ▸ | CA7 | P43166 | 2/20 | 0.61 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.60 |
| ▸ | CA3 | P07451 | 1/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL246218 | 0.88 | KDM4E (1.00) | KDM4ELCKALDH1A1HPGDCYP2D6 | |
| SCHEMBL29397959 | 0.88 | KDM4E (1.00) | KDM4ELCKALDH1A1HPGDCYP2D6 | |
| SCHEMBL12221062 | 0.88 | KDM4E (0.80) | KDM4ELCKALDH1A1HPGDCYP2D6 | |
| SCHEMBL22872003 | 0.85 | KDM4E (0.76) | KDM4ELCKALDH1A1HPGDCYP2D6 | |
| SCHEMBL22871876 | 0.84 | KDM4E (0.74) | KDM4ELCKALDH1A1HPGDCYP2D6 | |
| SCHEMBL344648 | 0.83 | CYP2D6 (0.72) | KDM4ELCKALDH1A1HPGDCYP2D6 | |
| SCHEMBL3194989 | 0.83 | KDM4E (0.72) | KDM4ELCKALDH1A1HPGDCYP2D6 | |
| SCHEMBL6031499 | 0.83 | CYP2D6 (0.76) | KDM4ELCKALDH1A1HPGDCYP2D6 | |
| SCHEMBL22871913 | 0.82 | KDM4E (0.71) | KDM4ELCKALDH1A1HPGDCYP2D6 | |
| SCHEMBL9387319 | 0.81 | CYP2D6 (0.74) | KDM4ELCKALDH1A1HPGDCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009911-A1 | Hepsin substrates and prodrugs | IRM, LLC (BM) | 2004-01-15 | — | — | US | claimed |
| WO-2003064620-A2 | HEPSIN SUBSTRATES AND PRODRUGS | IRM, LLC (BM) | 2003-08-07 | — | — | WO | claimed |
| WO-2003029823-A1 | COMBINATORIAL PROTEASE SUBSTRATE LIBRARIES | IRM LLC (BM) | 2003-04-10 | — | — | WO | claimed |
| WO-2017035501-A1 | SIALYLTRANSFERASE INHIBITORS AND USES THEREOF | ACADEMIA SINICA (TW) | 2017-03-02 | — | — | WO | disclosed |
| US-20080090863-A1 | Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20080032917-A1 | FLAVIVIRUS PROTEASE SUBSTRATES AND INHIBITORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2008-02-07 | — | — | US | disclosed |
| WO-2006014232-A2 | DENGUE PROTEASE SUBSTRATES AND INHIBITORS | IRM LLC (BM) | 2006-02-09 | — | — | WO | disclosed |
| US-20050222383-A1 | Prostasin substrates and inhibitors | IRM LLC (BM) | 2005-10-06 | — | — | US | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| WO-2005076886-A2 | PROSTASIN SUBSTRATES AND INHIBITORS | IRM LLC (BM) | 2005-08-25 | — | — | WO | disclosed |
| US-20040009911-A1 | Hepsin substrates and prodrugs | IRM, LLC (BM) | 2004-01-15 | — | — | US | disclosed |
| WO-2003064620-A2 | HEPSIN SUBSTRATES AND PRODRUGS | IRM, LLC (BM) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003029823-A1 | COMBINATORIAL PROTEASE SUBSTRATE LIBRARIES | IRM LLC (BM) | 2003-04-10 | — | — | WO | disclosed |
| US-20030059847-A1 | Combinatorial protease substrate libraries | IRM, LLC (BM) | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009911-A1 | Hepsin substrates and prodrugs | HPN, SPR, TMPRSS15 | KDM4E 4130/4885LCK 4125/4885ALDH1A1 2407/4885 |
| US-20080090863-A1 | Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor | MCHR1, GPR119, MCHR2 | KDM4E 628/4885LCK 982/4885ALDH1A1 1549/4885 |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | KDM4E 1190/4885LCK 1697/4885ALDH1A1 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.